Our research and development team derived from the scientific research team of Prof. Nancy IP in The Hong Kong University of Science and Technology and has dedicated to the research of Alzheimer’s disease diagnosis and treatment methods, and has successively achieved breakthrough progress and innovative results. Utilizing world-leading proteomic technology – ultrasensitive and high-throughput blood-based protein measurement technology (i.e. Proximity Extension Assay), combining proprietary machine learning algorithms, our technology can detect AD 5-10 years before clinical symptoms manifest. This technology enables us to provide not only early screening and risk prediction, but also personal advice, multi-dimensional analysis, and close monitoring to the individual be tested.
Achieve detection at 5 - 10 years before AD Symptoms manifest
Distinguish individuals with different levels of AD risks
Provide personalized analysis and suggestions
Evaluate the status of different human body systems related to AD
Provide regular testing service to closely monitor AD risk or progression
2023 by Cognitact Ltd.All right reserved.
